Transdermal drug delivery in Parkinson's disease

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The long-term management of Parkinson's disease is compromised by the development of treatment-related complications that can severely limit the effectiveness of levodopa. Growing evidence implicates intermittent, or pulsatile, stimulation of dopamine receptors as one potential mechanism in their genesis. Continuous administration of medication via the transdermal route offers a potential avenue to circumvent pulsatile-drug delivery and, thus, possibly deflect development of dyskinesia and motor fluctuations. The development of an effective transdermal drug preparation for Parkinson's disease has had a long gestation, but the recent emergence of rotigotine as an effective transdermal therapy provides hope and encouragement that additional advances may also be forthcoming and that our ability to effectively treat this devastating disease will continue to grow.

Original languageEnglish (US)
Pages (from-to)471-482
Number of pages12
JournalAging Health
Volume3
Issue number4
DOIs
StatePublished - Aug 2007
Externally publishedYes

Fingerprint

Parkinson Disease
Drug Compounding
Dyskinesias
Dopamine Receptors
Levodopa
Pharmaceutical Preparations
Pregnancy
Therapeutics
N 0437

Keywords

  • Apomorphine
  • Levodopa
  • Lisuride
  • Motor response complications
  • Parkinson's disease
  • Rotigotine transdermal

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Medicine(all)

Cite this

Transdermal drug delivery in Parkinson's disease. / Pfeiffer, Ronald.

In: Aging Health, Vol. 3, No. 4, 08.2007, p. 471-482.

Research output: Contribution to journalArticle

@article{78866a5f26b64e50b7ffee2e3d4d563f,
title = "Transdermal drug delivery in Parkinson's disease",
abstract = "The long-term management of Parkinson's disease is compromised by the development of treatment-related complications that can severely limit the effectiveness of levodopa. Growing evidence implicates intermittent, or pulsatile, stimulation of dopamine receptors as one potential mechanism in their genesis. Continuous administration of medication via the transdermal route offers a potential avenue to circumvent pulsatile-drug delivery and, thus, possibly deflect development of dyskinesia and motor fluctuations. The development of an effective transdermal drug preparation for Parkinson's disease has had a long gestation, but the recent emergence of rotigotine as an effective transdermal therapy provides hope and encouragement that additional advances may also be forthcoming and that our ability to effectively treat this devastating disease will continue to grow.",
keywords = "Apomorphine, Levodopa, Lisuride, Motor response complications, Parkinson's disease, Rotigotine transdermal",
author = "Ronald Pfeiffer",
year = "2007",
month = "8",
doi = "10.2217/1745509X.3.4.471",
language = "English (US)",
volume = "3",
pages = "471--482",
journal = "Aging Health",
issn = "1745-509X",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - Transdermal drug delivery in Parkinson's disease

AU - Pfeiffer, Ronald

PY - 2007/8

Y1 - 2007/8

N2 - The long-term management of Parkinson's disease is compromised by the development of treatment-related complications that can severely limit the effectiveness of levodopa. Growing evidence implicates intermittent, or pulsatile, stimulation of dopamine receptors as one potential mechanism in their genesis. Continuous administration of medication via the transdermal route offers a potential avenue to circumvent pulsatile-drug delivery and, thus, possibly deflect development of dyskinesia and motor fluctuations. The development of an effective transdermal drug preparation for Parkinson's disease has had a long gestation, but the recent emergence of rotigotine as an effective transdermal therapy provides hope and encouragement that additional advances may also be forthcoming and that our ability to effectively treat this devastating disease will continue to grow.

AB - The long-term management of Parkinson's disease is compromised by the development of treatment-related complications that can severely limit the effectiveness of levodopa. Growing evidence implicates intermittent, or pulsatile, stimulation of dopamine receptors as one potential mechanism in their genesis. Continuous administration of medication via the transdermal route offers a potential avenue to circumvent pulsatile-drug delivery and, thus, possibly deflect development of dyskinesia and motor fluctuations. The development of an effective transdermal drug preparation for Parkinson's disease has had a long gestation, but the recent emergence of rotigotine as an effective transdermal therapy provides hope and encouragement that additional advances may also be forthcoming and that our ability to effectively treat this devastating disease will continue to grow.

KW - Apomorphine

KW - Levodopa

KW - Lisuride

KW - Motor response complications

KW - Parkinson's disease

KW - Rotigotine transdermal

UR - http://www.scopus.com/inward/record.url?scp=35848944081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35848944081&partnerID=8YFLogxK

U2 - 10.2217/1745509X.3.4.471

DO - 10.2217/1745509X.3.4.471

M3 - Article

VL - 3

SP - 471

EP - 482

JO - Aging Health

JF - Aging Health

SN - 1745-509X

IS - 4

ER -